Slide 1: Welcome to the 1H23 webinar
Welcome to the 1H23 webinar August 18, 2023
Slide 2: This is Modulight
This is Modulight We fight cancer with science and technology ▪ We are a biomedical company ▪ We also manufacture products that designs and manufactures for other high-value applications laser devices for the treatment such as quantum computing of cancer and eye diseases and for genetics 2
Slide 3: Today's agenda
Today’s agenda ▪ H1 in brief ▪ US launch update ▪ Financial highlights ▪ R&D pipeline ▪ Revenue model and customer base ▪ Outlook ▪ Q&A 3
Slide 4: H1 in brief
H1 in brief ▪ Positive development continued: ▪ Product development projects and customer relationships ▪ Development of SaaS-based business models We believe that actions in line with our growth ▪ Start-up of US operations strategy and our long-term ▪ Revenue EUR 2,600 thousand investment program w
Slide 5: U.S. launch update
U.S. launch update Lorem ipsum ▪ In January, pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) for our laser device for the treatment of wet age-related macular degeneration (AMD) ▪ First product support center on the East Coast ▪ Visits to customers in hospitals ▪ Pay per t
Slide 6: Financial highlights April–June 2023
Financial highlights April–June 2023 ▪ Revenue +122% YoY due to delivery of existing projects ▪ Improvement in Revenue EBITDA EBIT profitability ▪ Operating costs slightly higher YoY dues to growth strategy EUR EUR EUR implementation 1,107 -1,581 -2,095 ▪ Due to completed investment program thousand
Slide 7: Financial highlights January–June 2023
Financial highlights January–June 2023 ▪ Revenue +23.8% YoY due to delivery of existing projects ▪ Slight improvement in EBITDA-% Revenue EBITDA EBIT ▪ Operating costs grew YoY due to growth strategy implementation EUR EUR EUR ▪ Due to completed investment program 2,600 -3,010 -3,998 costs & CAPEX a
Slide 8: Key figures
Key figures Group EUR 1,000 unless otherwise noted 4–6/2023 4–6/2022 1–6/2023 1–6/2022 1–12/2022 1) Revenue 1,107 498 2,600 2,100 4,599 EBITDA -1,581 -2,176 -3,010 -2,594 -5,936 EBITDA - % -142.8% -436.8% -115.8% -123.5% -129.1% Operating result (EBIT) -2,095 -2,610 -3,998 -3,480 -7,792 Operating re
Slide 9: Strategic programs
Strategic programs 1. Sales, marketing and 2. Cloud technology and cloud 3. Productizing platform devices for operations development based service development various indications & applications 4. Technology development based on 5. Development of ESG, the completed investment program governance and
Slide 10: Solid R&D pipeline
▪ 27 projects Solid R&D pipeline ▪ Projects progressed well, significant revenue potential Number of projects with commercialization potential ▪ Positive development in 30 e.g. cloud technology related to treatment of 25 bladder cancer and eye diseases, in new business 20 models and related clinical
Slide 11: Modulight's customer base
Modulight’s customer base Customer ownership 30 ▪ 11% are research companies 25 ▪ 30% are privately owned 20 ▪ 59% of customers are 15 listed companies 10 ▪ 63% are established companies 5 ▪ 30% have over 1bn revenue 0 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 Hospitals and research institutions Priva
Slide 12: Economics and Pay Per Treatment
Economics and Pay Per Treatment ▪ An analysis of the product development pipeline potential was finalized with KPMG in Q3 2022. In addition to the other ▪ The results and further studies have now benefits to patients, we believe our treatment with been used to analyse the pricing for the this pricin
Slide 13: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts share of pharmaceutical or treatment principle, without revenue risk for Modulight fees, or the utilization rate of industrial applications. Predictability of Modulight’s revenue is improving Curre
Slide 14: Outlook
Outlook Modulight has not issued guidance for revenue or profitability in 2023. As the company’s customer projects are still distributed across varying early stages of development, and predicting developments in the market remains challenging, it is difficult to forecast performance in 2023. However
Slide 15: Summary
Summary ▪ Positive development continued with R&D pipeline, customer interaction & new business models. ▪ Discussions with new partners progressed well, and number of customer meetings continued to grow. ▪ Product development pipeline stayed at record level with 27 projects, and several projects pro
Slide 16: Thank you! Questions?
Thank you! Questions? modulight
Slide 17: Thank you
Thank you Please follow us in social media